\
&
Contact us
Published on | 3 years ago
ProgrammesIn the European Innovation Council 2022 work programme four recognition prizes are included with upcoming calls for applications.
More info on how to apply for the competitions
“The European Innovation Procurement Awards aim to recognise public and private buyers, natural persons and those legal entities supporting these practices across Europe in their efforts to promote and stimulate innovation procurement and the innovative ways the solutions are procured. The Awards also aims to demonstrate how innovation procurement positively transforms the economy by not only creating new and sustainable markets, but also by tackling societal challenges such as climate change.” (EIC 2022 WP). There are three categories. In each category a winner will be awarded with 75.000 euro (1st ranked) and one runner up (ranked 2nd) with 25.000 euro.
The prize awards cities that boost the local innovation ecosystem and new activities aimed at game-changing innovation. There are two categories:
The prize celebrates women who have founded an innovative company. There are two categories:
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.